Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat.
The majority of J&J's near-term patent losses are for products that are hard to manufacture, which should reduce the intensity of generic competition.
J&J's late-stage drug pipeline is relatively weak for the size of the company, which could create long-term headwinds for growth.
|
Metric
|
JNJ
|
LLY
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.40 | 81.48 | 17.37 |
Price/Book Value | 5.43 | 60.37 | 6.58 |
Price/Sales | 4.58 | 21.11 | 4.61 |
Price/Cash Flow | 17.42 | 81.86 | 15.37 |
|
Metric
|
JNJ
|
LLY
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.77 | 0.61 | 0.88 |
Current Ratio | 1.07 | 1.11 | 1.47 |
Interest Coverage | 24.45 | 15.08 | 13.07 |
|
Metric
|
JNJ
|
LLY
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 13.17% | 13.15% | 15.46% |
Return on Equity (Normalized) | 32.42% | 69.16% | 41.15% |
Return on Invested Capital (Normalized) | 20.93% | 23.97% | 22.92% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Qjtxxlntsf | Bxd | $818.8 Bil | |||
| AbbVie Inc
ABBV
| Dfskbcvq | Qltq | $339.0 Bil | |||
| Merck & Co Inc
MRK
| Mtqwwkms | Xpgrz | $286.7 Bil | |||
| Roche Holding AG ADR
RHHBY
| Kvrrmvbsh | Txl | $255.9 Bil | |||
| AstraZeneca PLC ADR
AZN
| Svgmmqyw | Bskg | $241.9 Bil | |||
| Novartis AG ADR
NVS
| Kgxkxdfz | Ymfr | $233.0 Bil | |||
| Amgen Inc
AMGN
| Bgkfvwfsj | Ppxf | $171.5 Bil | |||
| Pfizer Inc
PFE
| Vthnlgyb | Mdtp | $164.2 Bil | |||
| Sanofi SA ADR
SNY
| Cnnwcjtg | Gcz | $142.8 Bil |
:quality(80)/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
United States